Baidu
map

扎那米韦是否可安全有效治疗重度流感患儿?

2016-10-31 MedSci MedSci原创

扎那米韦是一种流感病毒神经氨酸酶抑制剂,通过改变流感病毒在感染细胞内的聚集和释放,发挥预防和治疗流感的目的。据ID Week 2016上展示的一项新的研究显示,对于高风险并发症和无法耐受肠内给药的住院儿童来说,使用静脉扎那米韦来抗流感治疗或有较好的安全性和耐受性。研究人员共招募了71名流感儿童和青少年(平均年龄为7岁),以评估静脉扎那米韦的疗效和安全性。年龄≤6岁且患病7天内住院的患者开始接受14

扎那米韦是一种流感病毒神经氨酸酶抑制剂,通过改变流感病毒在感染细胞内的聚集和释放,发挥预防和治疗流感的目的。据ID Week 2016上展示的一项新的研究显示,对于高风险并发症和无法耐受肠内给药的住院儿童来说,使用静脉扎那米韦来抗流感治疗或有较好的安全性和耐受性。

研究人员共招募了71名流感儿童和青少年(平均年龄为7岁),以评估静脉扎那米韦的疗效和安全性。年龄≤6岁且患病7天内住院的患者开始接受14毫克/公斤的扎那米韦,应用5-10天,患者年龄在6-18岁之间的儿童接受12-600毫克/公斤至,应用5至10天。随访23天,评估扎那米韦的有效性、安全性、临床结局和病毒学。

结果显示,72%的患者发生了不良事件,21%的患者发生了严重的不良事件,包括5名患者死亡。65名患者需入住ICU,56%的患者存在其他慢性疾病。然而,这些副作用似乎与扎那米韦并无关联。

研究并未发现与药物相关的不良反应,因此研究人员认为扎那米韦为重度流感儿童提供了一种适当的治疗选择。

原始出处:

ate Sherrer.Zanamivir may be viable influenza treatment alternative in children. Healio, October 31, 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1619450, encodeId=bd8a16194500b, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Nov 02 10:02:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152587, encodeId=99f815258ea3, content=vvvvvbh, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Nov 01 09:59:03 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152433, encodeId=5d4e152433ae, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Mon Oct 31 19:56:36 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1619450, encodeId=bd8a16194500b, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Nov 02 10:02:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152587, encodeId=99f815258ea3, content=vvvvvbh, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Nov 01 09:59:03 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152433, encodeId=5d4e152433ae, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Mon Oct 31 19:56:36 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-11-01 为你把脉

    vvvvvbh

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1619450, encodeId=bd8a16194500b, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Nov 02 10:02:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152587, encodeId=99f815258ea3, content=vvvvvbh, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Nov 01 09:59:03 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152433, encodeId=5d4e152433ae, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Mon Oct 31 19:56:36 CST 2016, time=2016-10-31, status=1, ipAttribution=)]
    2016-10-31 上邪zyy

    了解一下

    0

Baidu
map
Baidu
map
Baidu
map